Andrea S Shin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1093292/publications.pdf

Version: 2024-02-01

45 papers	1,592 citations	430874 18 h-index	302126 39 g-index
45 all docs	45 docs citations	45 times ranked	1921 citing authors

#	Article	IF	Citations
1	Associations of Habitual Dietary Intake With Fecal Short-Chain Fatty Acids and Bowel Functions in Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2022, 56, 234-242.	2.2	5
2	The Transition From Rome III to Rome IV Irritable Bowel Syndrome: What We Gain and Lose. Clinical Gastroenterology and Hepatology, 2022, 20, 508-510.	4.4	6
3	Early adverse life events and postâ€traumatic stress disorder in patients with constipation and suspected disordered defecation. Neurogastroenterology and Motility, 2022, 34, e14195.	3.0	8
4	Relationships of Intestinal Lactase and the Small Intestinal Microbiome with Symptoms of Lactose Intolerance and Intake in Adults. Digestive Diseases and Sciences, 2022, 67, 5617-5627.	2.3	2
5	Associations of Food Intolerance with Irritable Bowel Syndrome, Psychological Symptoms, and Quality of Life. Clinical Gastroenterology and Hepatology, 2022, 20, 2121-2131.e3.	4.4	6
6	Delayed Gastric Emptying Is Not Associated with a Microbiological Diagnosis of Small Intestinal Bacterial Overgrowth. Digestive Diseases and Sciences, 2021, 66, 160-166.	2.3	3
7	COVID-19 Epidemiology and Google Searches. Clinical Gastroenterology and Hepatology, 2021, 19, 406-407.	4.4	0
8	High prevalence of food intolerances among US internet users. Public Health Nutrition, 2021, 24, 531-535.	2.2	9
9	Short-chain fatty acid and fecal microbiota profiles are linked to fibrosis in primary biliary cholangitis. FEMS Microbiology Letters, 2021, 368, .	1.8	16
10	The changing prevalence of functional constipation: why words matter. The Lancet Gastroenterology and Hepatology, 2021, 6, 600-602.	8.1	3
11	Feeling gutted in chronic kidney disease (CKD): Gastrointestinal disorders and therapies to improve gastrointestinal health in individuals CKD, including those undergoing dialysis. Seminars in Dialysis, 2021, , .	1.3	7
12	Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey. Gastroenterology, 2020, 158, 786-788.e1.	1.3	33
13	Acute Diarrheal Illness. Gastroenterology, 2020, 158, 838-839.	1.3	0
14	Information- and Health-care Seeking Behaviors in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2020, 18, 2840-2842.	4.4	5
15	Risk Factors Associated With Upper Aerodigestive Tract or Coliform Bacterial Overgrowth of the Small Intestine in Symptomatic Patients. Journal of Clinical Gastroenterology, 2020, 54, 150-157.	2.2	8
16	Potential Benefit With Complementary and Alternative Medicine in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2020, 19, 1538-1553.e14.	4.4	12
17	Association Between Proteomic Blood Biomarkers and DTI/NODDI Metrics in Adolescent Football Players: A Pilot Study. Frontiers in Neurology, 2020, 11, 581781.	2.4	11
18	Lactose Intolerance. Mayo Clinic Proceedings, 2020, 95, 1499-1505.	3.0	18

#	Article	IF	Citations
19	Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results From the IBS in America Survey. Clinical Gastroenterology and Hepatology, 2019, 17, 2471-2478.e3.	4.4	65
20	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 573-574.	4.4	0
21	Associations of chronic diarrhoea with non-alcoholic fatty liver disease and obesity-related disorders among US adults. BMJ Open Gastroenterology, 2019, 6, e000322.	2.7	6
22	Characterization of Proximal Small Intestinal Microbiota in Patients With Suspected Small Intestinal Bacterial Overgrowth: A Cross-Sectional Study. Clinical and Translational Gastroenterology, 2019, 10, e00073.	2.5	13
23	Refers to: Paul Enck. Not more, but less studies are warrantedâ€"If you take your metaâ€analysis seriously. Neurogastroenterology and Motility, 2019, 31, e13490.	3.0	0
24	AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Clinical Gastroenterology and Hepatology, 2019, 17, 380-390.e1.	4.4	104
25	The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders. Clinical Gastroenterology and Hepatology, 2019, 17, 256-274.	4.4	119
26	2103 Fecal bile acids, fecal short-chain fatty acids, and the intestinal microbiota in patients with irritable bowel syndrome (IBS) and control volunteers. Journal of Clinical and Translational Science, 2018, 2, 12-13.	0.6	0
27	Systematic review and metaâ€analysis: Efficacy of patented probiotic, <scp>VSL</scp>#3, in irritable bowel syndrome. Neurogastroenterology and Motility, 2018, 30, e13427.	3.0	27
28	Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. Clinical Gastroenterology and Hepatology, 2017, 15, 166-174.	4.4	109
29	Introduction of Clinical Practice Update Committee Articles. Clinical Gastroenterology and Hepatology, 2017, 15, 4.	4.4	4
30	Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders. Clinical Gastroenterology and Hepatology, 2017, 15, 1844-1854.	4.4	43
31	Patient considerations in the management of chronic constipation: focus on prucalopride. Patient Preference and Adherence, 2016, Volume 10, 1373-1384.	1.8	8
32	Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome. Clinical and Translational Gastroenterology, 2016, 7, e173.	2.5	70
33	Introduction to Clinical Practice Update Committee Articles. Gastroenterology, 2016, 151, 45.	1.3	0
34	Therapeutic Applications of Ghrelin Agonists in the Treatment of Gastroparesis. Current Gastroenterology Reports, 2015, 17, 430.	2.5	19
35	A Randomized Trial of 5-Hydroxytryptamine4â€"Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation. Clinical Gastroenterology and Hepatology, 2015, 13, 701-708.e1.	4.4	25
36	Quantitative Gastrointestinal and Psychological Traits Associated With Obesity and Response to Weight-Loss Therapy. Gastroenterology, 2015, 148, 537-546.e4.	1.3	143

#	Article	IF	Citations
37	Systematic review with metaâ€analysis: highly selective 5â€HT4 agonists (prucalopride, velusetrag or) Tj ETQq1 1 0.784314 rgBT /Ov	3.7	126
38	Novel association of rectal evacuation disorder and rumination syndrome: Diagnosis, comorbidities, and treatment. United European Gastroenterology Journal, 2014, 2, 38-46.	3.8	32
39	Effect of Increased Bile Acid Synthesis or Fecal Excretion in Irritable Bowel Syndrome-Diarrhea. American Journal of Gastroenterology, 2014, 109, 1621-1630.	0.4	82
40	Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion. American Journal of Physiology - Renal Physiology, 2014, 307, G508-G516.	3.4	45
41	The Ghrelin Agonist RM-131 Accelerates Gastric Emptying of Solids and Reduces Symptoms in Patients With Type 1 Diabetes Mellitus. Clinical Gastroenterology and Hepatology, 2013, 11, 1453-1459.e4.	4.4	97
42	Bowel Functions, Fecal Unconjugated Primary and Secondary Bile Acids, and Colonic Transit in Patients With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2013, 11, 1270-1275.e1.	4.4	132
43	Interpretation of overall colonic transit in defecation disorders in males and females. Neurogastroenterology and Motility, 2013, 25, 502.	3.0	18
44	Diagnostic Assessment of Diabetic Gastroparesis. Diabetes, 2013, 62, 2667-2673.	0.6	60
45	Randomized Controlled Phase Ib Study of Ghrelin Agonist, RM-131, in Type 2 Diabetic Women With Delayed Gastric Emptying. Diabetes Care, 2013, 36, 41-48.	8.6	93